On Thursday, May 15th The Colorado Psychedelic Society (CPS) is holding a fundraiser to support their mission of promoting awareness and education about the responsible use of psychedelics for healing. It will be a wonderful experiential event also featuring Zach Leary (son of Timothy Leary) as the keynote speaker. Space is limited so get your tickets here before it sells out!
Tri-Wellness supports CPS and its mission because of all the exciting research and recent developments in psychedelic medicine research and the exciting possibilities the future holds to help people with serious mental health struggles. (These findings reflect ongoing studies from reputable institutions and are intended for educational purposes only.)
**Always consult with your doctor before trying any of these medicines. Psychedelics are contraindicated for certain conditions so it is vital to consult with your doctor.**
Read on for the most recent research studies on Various psychedelic medicines.
Psilocybin (Magic Mushrooms):
- Depression & Burnout:
A University of Washington study found that psilocybin-assisted therapy led to a 21.33-point reduction in depression scores among frontline COVID-19 clinicians, compared to 9.33 in the placebo group.
Source: Axios - Parkinson’s Disease:
A Neuropsychopharmacology study reported that a single psilocybin dose improved both mood and motor symptoms in Parkinson’s patients for several weeks without serious adverse effects.
Source: Neuropsycopharmacology - Major Depressive Disorder (MDD):
The Usona Institute is conducting a Phase 3 clinical trial with 240 participants to test psilocybin for treatment-resistant MDD.
Source: Usona Institute
MDMA (Ecstasy):
- Post-Traumatic Stress Disorder (PTSD):
MDMA-assisted psychotherapy is showing promise in treating complex PTSD by supporting emotional breakthroughs during therapy.
Source: The Australian
LSD (Lysergic Acid Diethylamide):
- Generalized Anxiety Disorder (GAD):
MindMed’s MM120 (LSD-derived) treatment received FDA Breakthrough Therapy Designation after Phase 2 trials showed notable reductions in anxiety symptoms.
Source: Mindmed
⚠️ Important Safety Information
Potential Risks Identified:
- A Canadian population study of 9.2 million people found a 3.5x increased risk of schizophrenia diagnosis following hallucinogen-related ER visits.
Source: Institute for Clinical Evaluative Sciences
- Experts emphasize the importance of using psychedelics in controlled therapeutic settings due to risks such as anxiety, traumatic flashbacks, and Hallucinogen Persisting Perception Disorder (HPPD).
Source: The Guardian
🚫 Conditions Where Psychedelics May Be Too Risky
While research is promising, psychedelics are not universally safe. They are typically contraindicated or used with extreme caution in individuals with:
- Psychotic disorders (e.g., schizophrenia, schizoaffective disorder)
- Bipolar I disorder, due to the risk of inducing manic episodes
- Severe personality disorders where dissociation or emotional regulation is compromised
- Uncontrolled epilepsy or neurological instability
- A personal or family history of psychosis
It is critical to assess individual risks in consultation with a qualified medical professional before considering psychedelic therapies.
